In higher-risk, statin-intolerant adults with diabetes, bempedoic acid reduced MACE at a median 3 y

Michelle Kelsey; L Kristin Newby

doi:10.7326/J24-0016

In higher-risk, statin-intolerant adults with diabetes, bempedoic acid reduced MACE at a median 3 y

Ann Intern Med. 2024 Apr;177(4):JC39. doi: 10.7326/J24-0016. Epub 2024 Apr 2.

Authors

Michelle Kelsey¹, L Kristin Newby¹

Affiliation

¹ Duke University School of Medicine, Durham, North Carolina, USA (M.K., L.K.N.).

PMID: 38560908
DOI: 10.7326/J24-0016

Abstract

Ray KK, Nicholls SJ, Li N, et al; CLEAR OUTCOMES Committees and Investigators. Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial. Lancet Diabetes Endocrinol. 2024;12:19-28. 38061370.

Publication types

Randomized Controlled Trial

MeSH terms

Adult
Diabetes Mellitus* / drug therapy
Dicarboxylic Acids / adverse effects
Fatty Acids / adverse effects
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / adverse effects

Substances

8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid
Dicarboxylic Acids
Fatty Acids
Hydroxymethylglutaryl-CoA Reductase Inhibitors